Your browser doesn't support javascript.
loading
Genome-wide cell-free DNA fragmentation in patients with cancer.
Cristiano, Stephen; Leal, Alessandro; Phallen, Jillian; Fiksel, Jacob; Adleff, Vilmos; Bruhm, Daniel C; Jensen, Sarah Østrup; Medina, Jamie E; Hruban, Carolyn; White, James R; Palsgrove, Doreen N; Niknafs, Noushin; Anagnostou, Valsamo; Forde, Patrick; Naidoo, Jarushka; Marrone, Kristen; Brahmer, Julie; Woodward, Brian D; Husain, Hatim; van Rooijen, Karlijn L; Ørntoft, Mai-Britt Worm; Madsen, Anders Husted; van de Velde, Cornelis J H; Verheij, Marcel; Cats, Annemieke; Punt, Cornelis J A; Vink, Geraldine R; van Grieken, Nicole C T; Koopman, Miriam; Fijneman, Remond J A; Johansen, Julia S; Nielsen, Hans Jørgen; Meijer, Gerrit A; Andersen, Claus Lindbjerg; Scharpf, Robert B; Velculescu, Victor E.
Afiliação
  • Cristiano S; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Leal A; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Phallen J; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Fiksel J; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Adleff V; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Bruhm DC; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Jensen SØ; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Medina JE; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Hruban C; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • White JR; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Palsgrove DN; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Niknafs N; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Anagnostou V; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Forde P; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Naidoo J; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Marrone K; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Brahmer J; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Woodward BD; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Husain H; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • van Rooijen KL; Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
  • Ørntoft MW; Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
  • Madsen AH; Department of Medical Oncology, University Medical Center, Utrecht University, Utrecht, The Netherlands.
  • van de Velde CJH; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Verheij M; Department of Surgery, Herning Regional Hospital, Herning, Denmark.
  • Cats A; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Punt CJA; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Vink GR; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Grieken NCT; Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Koopman M; Department of Medical Oncology, University Medical Center, Utrecht University, Utrecht, The Netherlands.
  • Fijneman RJA; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
  • Johansen JS; Department of Medical Oncology, University Medical Center, Utrecht University, Utrecht, The Netherlands.
  • Nielsen HJ; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Meijer GA; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Andersen CL; Department of Surgical Gastroenterology 360, Hvidovre Hospital, Hvidovre, Denmark.
  • Scharpf RB; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Velculescu VE; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Nature ; 570(7761): 385-389, 2019 06.
Article em En | MEDLINE | ID: mdl-31142840
ABSTRACT
Cell-free DNA in the blood provides a non-invasive diagnostic avenue for patients with cancer1. However, characteristics of the origins and molecular features of cell-free DNA are poorly understood. Here we developed an approach to evaluate fragmentation patterns of cell-free DNA across the genome, and found that profiles of healthy individuals reflected nucleosomal patterns of white blood cells, whereas patients with cancer had altered fragmentation profiles. We used this method to analyse the fragmentation profiles of 236 patients with breast, colorectal, lung, ovarian, pancreatic, gastric or bile duct cancer and 245 healthy individuals. A machine learning model that incorporated genome-wide fragmentation features had sensitivities of detection ranging from 57% to more than 99% among the seven cancer types at 98% specificity, with an overall area under the curve value of 0.94. Fragmentation profiles could be used to identify the tissue of origin of the cancers to a limited number of sites in 75% of cases. Combining our approach with mutation-based cell-free DNA analyses detected 91% of patients with cancer. The results of these analyses highlight important properties of cell-free DNA and provide a proof-of-principle approach for the screening, early detection and monitoring of human cancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Genoma Humano / Fragmentação do DNA / DNA Tumoral Circulante / Neoplasias Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Genoma Humano / Fragmentação do DNA / DNA Tumoral Circulante / Neoplasias Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos